Menu Search
Equities

Phaxiam Therapeutics SA

PHXM:PAR

Phaxiam Therapeutics SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)1.76
  • Today's Change-0.076 / -4.14%
  • Shares traded11.16k
  • 1 Year change-59.05%
  • Beta1.7835
Data delayed at least 15 minutes, as of Nov 12 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Phaxiam Therapeutics SA's revenues fell -80.05% from 6.65m to 1.33m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 228.00k to a larger loss of 23.49m.
Gross margin--
Net profit margin-1,023.96%
Operating margin-1,023.82%
Return on assets-41.90%
Return on equity-84.18%
Return on investment-61.11%
More ▼

Cash flow in EURView more

In 2023, cash reserves at Phaxiam Therapeutics SA fell by 28.32m. However, Cash Flow from Investing totalled 171.00k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 24.43m for operations while cash used for financing totalled 3.72m.
Cash flow per share-1.88
Price/Cash flow per share--
Book value per share2.54
Tangible book value per share-2.30
More ▼

Balance sheet in EURView more

Phaxiam Therapeutics SA has a Debt to Total Capital ratio of 45.56%, a higher figure than the previous year's 30.33%.
Current ratio0.3796
Quick ratio--
Total debt/total equity0.8368
Total debt/total capital0.4556
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.